BioSpace News Archive

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, a

Supporting the Company’s Global Expansion to Meet Growing Clinical and Biopharma Demand for Data-Driven Medicine - SOPHiA GENETICS enters next stage of its global expansion with oversubscribed Series F round exceeding $110 million, led by major health-tech fund and followed by strategic industry leader - Company demonstrates solidity of its business model with banks joining in the round - Didier Hirsch, former CFO at Agilent, joins the company’s Board of Directors a

Provention Bio, Inc. (Nasdaq:PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, yesterday launched a national effort to redefine patient care in type 1 diabetes (T1D) with t

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that it has dosed the first pa

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced FDA Investigational Device Exemption (IDE) approval and initiation of a pivotal study to evaluate the treatment of sebaceous hyperplasia (SH) lesions using the CellFX® System. The data generated from

Aegle Therapeutics Corporation today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AGLE-102™ for the treatment of patients with dystrophic epidermolysis bullosa (“DEB”), a rare genetic pediatric skin blistering disorder. AGLE-102 is an extracellular vesicle (“EV”) therapy that deliv

Editas Medicine, Inc., a leading genome editing company, announced that management will participate in the following upcoming investor conference:

Milestone Scientific Inc., a leading developer of computerized drug delivery instruments that provides painless and precise injections, announced that it projects sales for the third quarter ending September 30, 2020 increased sequentially more than five-fold versus the second quarter ending June 30, 2020.

Teneobio, Inc. and its affiliate TeneoTwo, Inc. announced that their investigational new drug application for TNB-486, a bispecific T-cell engaging antibody for the treatment of B-Cell Non-Hodgkin’s lymphoma was cleared for the initiation of Phase I clinical studies by the US Food and Drug Administration on September 30, 2020.

Dr. Runge brings 35 years’ experience as an Emergency Medicine Physician, Federal Government Executive and Public Policy Strategist.